title: Symptom-based tendencies of Helicobacter pylori eradication in patients with functional dyspepsia.
abstract: OBJECTIVE
  To investigate whether there were symptom-based tendencies in the Helicobacter pylori (H. pylori) eradication in functional dyspepsia (FD) patients.
  
  
  METHODS
  A randomized, single-blind, placebo-controlled study of H. pylori eradication for FD was conducted. A total of 195 FD patients with H. pylori infection were divided into two groups: 98 patients in the treatment group were treated with rabeprazole 10 mg twice daily for 2 wk, amoxicillin 1.0 g and clarithromycin 0.5 g twice daily for 1 wk; 97 patients in the placebo group were given placebos as control. Symptoms of FD, such as postprandial fullness, early satiety, nausea, belching, epigastric pain and epigastric burning, were assessed 3 mo after H. pylori eradication.
  
  
  RESULTS
  By per-protocol analysis in patients with successful H. pylori eradication, higher effective rates of 77.2% and 82% were achieved in the patients with epigastric pain and epigastric burning than those in the placebo group (P < 0.05). The effective rates for postprandial fullness, early satiety, nausea and belching were 46%, 36%, 52.5% and 33.3%, respectively, and there was no significant difference from the placebo group (39.3%, 27.1%, 39.1% and 31.4%) (P > 0.05). In 84 patients who received H. pylori eradication therapy, the effective rates for epigastric pain (73.8%) and epigastric burning (80.7%) were higher than those in the placebo group (P < 0.05). The effective rates for postprandial fullness, early satiety, nausea and belching were 41.4%, 33.3%, 50% and 31.4%, respectively, and did not differ from those in the placebo group (P > 0.05). By intention-to-treat analysis, patients with epigastric pain and epigastric burning in the treatment group achieved higher effective rates of 60.8% and 65.7% than the placebo group (33.3% and 31.8%) (P < 0.05). The effective rates for postprandial fullness, early satiety, nausea and belching were 34.8%, 27.9%, 41.1% and 26.7% respectively in the treatment group, with no significant difference from those in the placebo group (34.8%, 23.9%, 35.3% and 27.1%) (P > 0.05).
  
  
  CONCLUSIONS
  The efficacy of H. pylori eradication has symptom-based tendencies in FD patients. It may be effective in the subgroup of FD patients with epigastric pain syndrome.
authors.affiliation: Department of Gastroenterology, the People's Hospital of Henan Province, Zhengzhou 450003, Henan Province, China.
authors.forename: Ling
authors.initials: L
authors.lastname: Lan
authors.forename: Jing
authors.initials: J
authors.lastname: Yu
authors.forename: Yu-Long
authors.initials: YL
authors.lastname: Chen
authors.forename: Ya-Li
authors.initials: YL
authors.lastname: Zhong
authors.forename: Hao
authors.initials: H
authors.lastname: Zhang
authors.forename: Chang-He
authors.initials: CH
authors.lastname: Jia
authors.forename: Yuan
authors.initials: Y
authors.lastname: Yuan
authors.forename: Bo-Wei
authors.initials: BW
authors.lastname: Liu
mesh_terms: D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D004415:Dyspepsia / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology*; D005260:Female; D016481:Helicobacter Infections / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology*; D016480:Helicobacter pylori / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010146:Pain; D010919:Placebos; D011446:Prospective Studies; D016037:Single-Blind Method; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D010919:Placebos